Cargando…
From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive p...
Autores principales: | Eichler, H‐G, Baird, LG, Barker, R, Bloechl‐Daum, B, Børlum‐Kristensen, F, Brown, J, Chua, R, Del Signore, S, Dugan, U, Ferguson, J, Garner, S, Goettsch, W, Haigh, J, Honig, P, Hoos, A, Huckle, P, Kondo, T, Le Cam, Y, Leufkens, H, Lim, R, Longson, C, Lumpkin, M, Maraganore, J, O'Rourke, B, Oye, K, Pezalla, E, Pignatti, F, Raine, J, Rasi, G, Salmonson, T, Samaha, D, Schneeweiss, S, Siviero, PD, Skinner, M, Teagarden, JR, Tominaga, T, Trusheim, MR, Tunis, S, Unger, TF, Vamvakas, S, Hirsch, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706805/ https://www.ncbi.nlm.nih.gov/pubmed/25669457 http://dx.doi.org/10.1002/cpt.59 |
Ejemplares similares
-
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need
por: Hirsch, G, et al.
Publicado: (2016) -
“Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
por: Eichler, H‐G, et al.
Publicado: (2016) -
The next frontier: Fostering innovation by improving health data access and utilization
por: Oye, KA, et al.
Publicado: (2015) -
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009) -
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
por: Eichler, Hans‐Georg, et al.
Publicado: (2020)